P. Costet

发表

Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis

Peter S. Kutchukian, A. Peier, Shirly Pinto, 2020, Cell reports. Medicine.

Shirly Pinto, P. Costet, J. Imbriglio, 2017 .

Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine

T. Willson, W. Wahli, T. Pineau, 2001 .

Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine.

T. Willson, W. Wahli, T. Pineau, 2001, The Biochemical journal.

PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

M. Krempf, R. Guérois, C. Langhi, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c*

M. Krempf, A. Grefhorst, B. Staels, 2006, Journal of Biological Chemistry.

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

M. Krempf, C. Langhi, B. Staels, 2008, FEBS letters.

Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

M. Krempf, T. Pineau, C. Laboisse, 2006, Endocrinology.

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.

B. Cariou, T. Konrad, M. Hoffmann, 2010, Atherosclerosis.

Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway.

T. Pineau, R. Barouki, B. Staels, 1998, Toxicology letters.

Knockout animals in toxicology: assessment of toxin bioactivation pathways using mice deficient in xenobiotic metabolizing enzymes.

P. Galtier, M. Alvinerie, T. Pineau, 1998, Toxicology letters.

Purification and characterization of a glutathione S-transferase Omega in pig: evidence for two distinct organ-specific transcripts.

T. Pineau, L. Debrauwer, P. Costet, 2001, The Biochemical journal.

CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines.

P. Beaune, I. de Waziers, A. Berger, 1996, Environmental toxicology and pharmacology.

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.

M. Krempf, M. Brindisi, L. Duvillard, 2011, Atherosclerosis.

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients.

M. Krempf, C. Langhi, C. Le May, 2010, Atherosclerosis.

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M400396-JLR200

N. Seidah, M. Krempf, H. Brewer, 2005, Journal of Lipid Research.

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9*

M. Krempf, C. Langhi, P. Nguyen, 2008, Journal of Biological Chemistry.

Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1

B. Pillot, X. Prieur, C. Le May, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia

M. Krempf, C. Langhi, A. Jarry, 2009, Arteriosclerosis, thrombosis, and vascular biology.

The 4S benzo(a)pyrene-binding protein is not a transcriptional activator of Cyp1a1 gene in Ah receptor-deficient (AHR -/-) transgenic mice.

P. Galtier, T. Pineau, P. Costet, 1998, Archives of biochemistry and biophysics.

Regulation and mechanisms of macrophage cholesterol efflux.

A. Tall, P. Costet, Nan Wang, 2002, The Journal of clinical investigation.

Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice

M. Lathrop, F. Matsuda, C. Mounier, 2013, Diabetologia.

PCSK9: a promising therapeutic target for dyslipidemias?

M. Krempf, G. Lambert, P. Costet, 2006, Trends in Endocrinology & Metabolism.

In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARalpha-deficient mice.

T. Pineau, F. Guéraud, A. Paris, 1999, Journal of lipid research.

[PCSK9: a new gene involved in familial hypercholesteremia].

M. Krempf, G. Lambert, P. Costet, 2004, Medecine sciences : M/S.

Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes.

P. Costet, M. Chétiveaux, Sanae Kourimate, 2009, Atherosclerosis.

A 037 IMPACT OF THE CYP 2 C 19 * 17 ALLELE ON PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS SUFFERING FROM NON — ST ELEVATION ACUTE CORONARY SYNDROME

P. Morange, J. Hulot, M. Alessi, 2009 .

Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.

K. Asehnoune, C. Langhi, L. Lagrost, 2013, The Journal of clinical endocrinology and metabolism.

Galactosylated multimodular lipoplexes for specific gene transfer into primary hepatocytes

B. Pitard, O. Lambert, R. Chèvre, 2008, The journal of gene medicine.

Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor.

A. Tall, Y. Luo, P Costet, 2000, The Journal of biological chemistry.

Molecular pathways and agents for lowering LDL-cholesterol in addition to statins.

P. Costet, 2010, Pharmacology & therapeutics.

Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells Expressing ABC1*

A. Tall, D. Silver, P. Costet, 2000, The Journal of Biological Chemistry.

Peroxisome Proliferator-activated Receptor α-Isoform Deficiency Leads to Progressive Dyslipidemia with Sexually Dimorphic Obesity and Steatosis*

P. Galtier, T. Pineau, A. Edgar, 1998, The Journal of Biological Chemistry.

Expression of cytochrome P‐450 3A in HT29‐MTX cells and Caco‐2 clone TC7

P. Beaune, A. Barbat, I. de Waziers, 1994, FEBS letters.

Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9

M. Krempf, C. Boileau, K. Ouguerram, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Retinoic Acid Receptor-Mediated Induction of ABCA1 in Macrophages

A. Tall, Marie-Christine Gerbod-Giannone, L. Gudas, 2003, Molecular and Cellular Biology.

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

R. Kreis, C. Boesch, M. Krempf, 2013, Nutrition & Metabolism.

Clinical aspects of PCSK9.

C. Le May, B. Cariou, Bertrand Cariou, 2011, Atherosclerosis.

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

Michel Krempf, M. Krempf, F. Pattou, 2009, Biochemical and biophysical research communications.

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.

M. Krempf, B. Cariou, P. Costet, 2008, Trends in biochemical sciences.

of ABCA 1 in Macrophages Retinoic Acid Receptor-Mediated Induction

A. Tall, Marie-Christine Gerbod-Giannone, L. Gudas, 2003 .

Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor.

Pascal G. P. Martin, H. Guillou, F. Lasserre, 2013, Journal of hepatology.

Effects of AFB1 on CYP 1A1, 1A2 and 3A6 mRNA, and P450 expression in primary culture of rabbit hepatocytes.

P. Galtier, T. Pineau, P. Guerre, 2000, Toxicology letters.

Impact of diabetes on remodelling, microvascular function and exercise capacity in aortic stenosis

P. Kellman, M. Jerosch-Herold, J. Greenwood, 2023, Open Heart.